Published in Clinicoecon Outcomes Res on February 13, 2013
Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis (2016) 1.48
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res (2015) 1.07
Variation in the risk of venous thromboembolism in people with colorectal cancer: a population-based cohort study from England. J Thromb Haemost (2014) 0.85
Implementing thrombosis guidelines in cancer patients: a review. Rambam Maimonides Med J (2014) 0.83
Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost (2016) 0.79
Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc (2015) 0.78
Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. Healthcare (Basel) (2016) 0.77
Direct Medical Costs Attributable to Cancer-Associated Venous Thromboembolism: A Population-Based Longitudinal Study. Am J Med (2016) 0.75
Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis. J Thromb Thrombolysis (2015) 0.75
Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. Cancer Invest (2016) 0.75
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. Thromb Res (2015) 0.75
Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma. Healthcare (Basel) (2016) 0.75
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria. Support Care Cancer (2017) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care (2005) 30.41
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood (2008) 2.97
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) (1999) 2.85
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Prediction of venous thromboembolism in cancer patients. Blood (2010) 2.31
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med (2006) 2.02
Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost (2002) 1.99
Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer (2010) 1.93
Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm (2007) 1.89
Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health (2006) 1.87
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78
Cancer and the prothrombotic state. Lancet Oncol (2002) 1.74
The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol (2004) 1.73
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer (2007) 1.60
Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm (2006) 1.33
Risk factors for venous thromboembolic events in cancer patients. Ann Oncol (2005) 1.32
Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med (2004) 1.26
Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol (2009) 1.11
Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program (2010) 1.01
The link between cancer and venous thromboembolism: a review. Am J Clin Oncol (2009) 1.00
Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. Ann Oncol (1997) 0.89
Are There Any Differences in the Clinical and Economic Outcomes Between US Cancer Patients Receiving Appropriate or Inappropriate Venous Thromboembolism Prophylaxis? J Oncol Pract (2009) 0.88
Primary prevention of venous thromboembolism in medical and surgical oncology patients. Br J Cancer (2010) 0.86
Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. J Thromb Thrombolysis (2009) 0.82
Clopidogrel versus prasugrel: times are changing, but not for everyone. Pharmacotherapy (2009) 0.78
Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol (2009) 3.68
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm (2007) 1.89
Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer (2012) 1.44
DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING. Endocr Pract (2015) 1.41
Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med (2010) 1.40
Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm (2006) 1.33
Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm (2007) 1.22
Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutter. Am J Cardiol (2011) 1.20
A comparison of depressive symptoms in stroke and primary care: applying Rasch models to evaluate the center for epidemiologic studies-depression scale. Value Health (2006) 1.11
Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol (2010) 1.11
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ (2012) 0.99
Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates. J Med Chem (2010) 0.95
Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther (2010) 0.95
Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. J Hosp Med (2012) 0.93
Cost of atrial fibrillation in United States managed care organizations. Adv Ther (2009) 0.92
Inpatient thromboprophylaxis use in U.S. hospitals: adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients. J Hosp Med (2009) 0.92
Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther (2013) 0.90
Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ (2013) 0.89
Are There Any Differences in the Clinical and Economic Outcomes Between US Cancer Patients Receiving Appropriate or Inappropriate Venous Thromboembolism Prophylaxis? J Oncol Pract (2009) 0.88
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis (2014) 0.88
Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ (2012) 0.88
Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med (2011) 0.87
Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost (2009) 0.87
Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract (1995) (2012) 0.86
Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother (2009) 0.86
Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL. Clin Appl Thromb Hemost (2010) 0.86
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Thromb Haemost (2008) 0.85
One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. Clin Ther (2011) 0.84
Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thromb Haemost (2008) 0.84
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol (2012) 0.83
Inhibition of Mrp2- and Ycf1p-mediated transport by reducing agents: evidence for GSH transport on rat Mrp2. Biochim Biophys Acta (2002) 0.83
Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors. J Med Econ (2012) 0.83
Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Adv Ther (2011) 0.82
Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. J Thromb Thrombolysis (2009) 0.82
Venous thromboembolism in the US: does race matter? J Thromb Thrombolysis (2011) 0.82
Preventing venous thromboembolism following orthopedic surgery in the United States: impact of special populations on clinical outcomes. Clin Appl Thromb Hemost (2011) 0.81
Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial. J Hosp Med (2011) 0.81
Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US. J Med Econ (2013) 0.80
Inpatient and outpatient occurrence of deep vein thrombosis and pulmonary embolism and thromboprophylaxis following selected at-risk surgeries. Ann Pharmacother (2011) 0.80
Hospital readmissions in US atrial fibrillation patients: occurrence and costs. Am J Ther (2013) 0.80
Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ (2011) 0.80
Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. Thromb Haemost (2009) 0.80
Type 2 diabetes mellitus treatment patterns in U.S. nursing home residents. Postgrad Med (2015) 0.79
PCR detection and analysis of potentially zoonotic Hepatitis E virus in French rats. Virol J (2014) 0.79
Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. Adv Ther (2014) 0.79
Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol (2008) 0.79
Appropriate VTE prophylaxis is associated with lower direct medical costs. Hosp Pract (1995) (2010) 0.79
Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy (2009) 0.79
Real-world rates of in-hospital and postdischarge deep-vein thrombosis and pulmonary embolism in at-risk medical patients in the United States. Clin Appl Thromb Hemost (2011) 0.78
Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis. Adv Ther (2012) 0.78
Retrospective administrative database study of the time period of venous thromboembolism risk during and following hospitalization for major orthopedic or abdominal surgery in real-world US patients. Hosp Pract (1995) (2011) 0.78
National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US. Adv Ther (2009) 0.78
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. J Med Econ (2014) 0.78
Update on tolvaptan for the treatment of hyponatremia. Expert Rev Pharmacoecon Outcomes Res (2012) 0.78
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy. Obstet Gynecol Int (2012) 0.78
Real-world evaluation of the effects of counseling and education in diabetes management. Diabetes Spectr (2014) 0.78
Total costs and atrial fibrillation ablation success or failure in Medicare-aged patients in the United States. Adv Ther (2010) 0.78
Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage. Community Ment Health J (2013) 0.77
Health care utilization, costs, and readmission rates associated with hyponatremia. Hosp Pract (1995) (2013) 0.77
Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis? J Thromb Thrombolysis (2010) 0.77
Need to improve thromboprophylaxis across the continuum of care for surgical patients. Adv Ther (2010) 0.77
Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia. Am J Clin Oncol (2015) 0.77
The impact of diabetes counseling and education: clinical and cost outcomes from a large population of US managed care patients with type 2 diabetes. Diabetes Educ (2013) 0.77
Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy. J Clin Psychopharmacol (2014) 0.77
Hospital-based costs associated with venous thromboembolism prophylaxis regimens. J Thromb Thrombolysis (2010) 0.76
The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients. Clinicoecon Outcomes Res (2012) 0.75
Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials. Medicine (Baltimore) (2017) 0.75
Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurol (2013) 0.75
Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. Adv Ther (2014) 0.75
Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. J Clin Psychopharmacol (2016) 0.75
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks. Cardiol Ther (2013) 0.75
Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. Inflamm Bowel Dis (2017) 0.75
Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States. J Manag Care Spec Pharm (2015) 0.75
Correction to: Steven Deitelzweig et al., Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin (2017) 0.75
Lack of thromboprophylaxis across the care continuum in US medical patients. Hosp Pract (1995) (2010) 0.75
Health care burden of dyspepsia among nonvalvular atrial fibrillation patients. J Manag Care Spec Pharm (2014) 0.75
Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Am J Ther (2014) 0.75
Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. J Thromb Thrombolysis (2015) 0.75
Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost (2008) 0.75
A practice-based research network focused on comparative effectiveness research in type 2 diabetes management. Postgrad Med (2013) 0.75
Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. J Med Econ (2011) 0.75